Perhaps novel approaches based on selective suppression of antigen-specific tumor Treg clones will yield better results than using monoclonal antibodies as functional markers characteristic of the general pool of effector Tregs such as PD-1/PD-L1 or CTLA-4. Here, CD274 is linked to neoplasm.